Corbus Pharmaceuticals Holdings, In... (CRBP)

$ 0.9511
-0.08 (-7.66%)
Symbol CRBP
Price $ 0.9511
Beta 1.940
Volume Avg. 0.96M
Market Cap 0.12B
Shares () -
52 Week Range 0.91-4.0
1y Target Est -
DCF Unlevered CRBP DCF ->
DCF Levered CRBP LDCF ->
ROE -126.28% Strong Sell
ROA -63.60% Strong Sell
Operating Margin -
Debt / Equity 56.72% Buy
P/E -
P/B 1.44 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest CRBP news

Mr. Yuval Cohen
Nasdaq Global Market

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.